Post on 03-Apr-2018
7/27/2019 Presentasi Jurnal Doc Arif
1/22
7/27/2019 Presentasi Jurnal Doc Arif
2/22
Introduction
Hepatitis C is a significant publichealth concern that affects ~4million Americans. It can progress to
severe liver disease, includingcirrhosis, liver failure, and hepatoma.Hepatitis C virus (HCV) is the
most common cause ofchronic hepatitis in this countryand is the most common
indication for liver
transplantation.
7/27/2019 Presentasi Jurnal Doc Arif
3/22
The incidence of newly diagnosedHCV infection is ~35,000 cases per
year. This represents a significantdecrease,compared with the incidence in
the 1980s (~180,000 cases peryear). The decline in theprevalence of HCV infection overthe past decade is largely due to
the decrease in transmission viablood transfusion that has
resulted from the screening of
blood donors.
7/27/2019 Presentasi Jurnal Doc Arif
4/22
AbstractTreatment guidelines recommend the useof peginterferon alfa-2b or peginterferonalfa-2a in combination with ribavirin forchronic hepatitis C virus (HCV) infection.However, these regimens have not beenadequately compared.
This article discuss the study of :
- sustained virologic response
- safety and adverse- event profiles
7/27/2019 Presentasi Jurnal Doc Arif
5/22
Between :Standard
dosepeginterfero
n alfa-2bregimen
low dose
peginterferonalfa-2b
regimen
Peginterfero
n alfa-2aregimen
7/27/2019 Presentasi Jurnal Doc Arif
6/22
Methods
3 treatments groups :
- Peginterferon alfa-2b standard dose
(1,5g/kgBB/week) + ribavirin
- Peginterferon alfa-2b low dose( 1,0g/kgBB/week) + ribavirin
- Peginterferon alfa-2a (180 g/week) +
ribavirin*oral ribavirin = 1000-1200 mg/day
7/27/2019 Presentasi Jurnal Doc Arif
7/22
Click icon to add picture
7/27/2019 Presentasi Jurnal Doc Arif
8/22
7/27/2019 Presentasi Jurnal Doc Arif
9/22
Patients criteria :
over 18 years old
hasdetectable HVC RNA level
has not been previously treated forhepatitis
C infection
not having coinfection with HIV
not having severe depression @ severe
psychiatric disorder
7/27/2019 Presentasi Jurnal Doc Arif
10/22
Efficacy assessment
Measure HCV RNA levels using CobasTaqman assay (Roche),which has lowerlimit of quantitation of 27 IU permililiter.
Measurements obtained during atweeks 2,4,12,24 and 48.
Considered failure if:
- insufficient virologic response atweek 12 @ 24. Therapy is discontinued.
7/27/2019 Presentasi Jurnal Doc Arif
11/22
Results
The rates of sustained virologicresponse did not differ significantlyamong the 3 treatment groups :
7/27/2019 Presentasi Jurnal Doc Arif
12/22
7/27/2019 Presentasi Jurnal Doc Arif
13/22
7/27/2019 Presentasi Jurnal Doc Arif
14/22
Discussion
The safety and adverse-eventprofiles and the efficacy data issimilar among patients with threedifferent regime.
Since monotherapy with standarddose peginterferon alfa-2b has beenassociated with higher rates ofvirologic response duringtreatment,these similar finding isunexpected.
7/27/2019 Presentasi Jurnal Doc Arif
15/22
Sustained virological response was lessfrequent among blacks and those with highbaseline HCV RNA level.
The magnitude of HCV RNA levelsuppression during the treatment phase islinked to sustained virologic response.
Virologic response during week 4 is animportant predictor of sustained virologicresponse:
- among 10% pts. who has undetectableHCV RNA level,86% had a sustainedvirological response
7/27/2019 Presentasi Jurnal Doc Arif
16/22
The time to the 1st undetectable HCV
RNA level was associated with theprobability of virologic relapse afterthe end of treatment:
- 50% patients who had HCV
suppresion for the 1st time by treatmentweek 24 also had virologic relapse ascompared with less than 10% at
treatment week 4.
7/27/2019 Presentasi Jurnal Doc Arif
17/22
Limitations :
Initial doses varied among patients Procedure for for ribavirin-dose
reduction differed between each
regimen group. Study is conducted in
US,comparative data may not
generelizable to other regions.
7/27/2019 Presentasi Jurnal Doc Arif
18/22
Literature review
7/27/2019 Presentasi Jurnal Doc Arif
19/22
7/27/2019 Presentasi Jurnal Doc Arif
20/22
7/27/2019 Presentasi Jurnal Doc Arif
21/22
Conclusion
Hepatitis C virus transmitted mainly via injectionof drug use (60%).
Hepatitis C chronic is treated with Peginterferonalfa combined with ribavirin to get a better result.
The outcomes of treatment
using both peginterferon alfa-2a
and 2b is similar.
7/27/2019 Presentasi Jurnal Doc Arif
22/22
THANK YOU
HANK YOUTHANK YOU